Clinical data | |
---|---|
Trade names | Awiqli |
Routes of administration | Subcutaneous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C280H435N71O87S6 |
Molar mass | 6380.33 g·mol−1 |
Insulin icodec, sold under the brand name Awiqli, is a medication used for the treatment of diabetes to improve glycemic control. [2] It is an ultralong-acting basal insulin analogue that is developed by Novo Nordisk. [2]
It has a plasma half-life more than eight days [5] (compared to 25 hours of the previous longest-acting insulin analogue insulin degludec), making it a once-weekly basal insulin. [5]
Like insulin, icodec is composed of two peptide chains linked by a disulfide bridge. However, a C20 fatty diacid-containing side chain has been added for strong, reversible albumin binding; and three amino acid substitutions provide molecular stability and attenuate insulin receptor binding and clearance. Together, these modifications prolong the half-life. [6]
Insulin icodec was approved for medical use in Canada in March 2024. [2]
In March 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Awiqli, intended for the treatment of diabetes. [3] The applicant for this medicinal product is Novo Nordisk A/S. [3] Insulin icodec was approved for medical use in the European Union in May 2024. [4]
Insulin icodec is the international nonproprietary name. [7]
Based on a clinical trial, glycemic control was found to be non-inferior with once-weekly insulin icodec compared with once-daily insulin glargine U100. [8]
Clinical data | |
---|---|
Trade names | Awiqli |
Routes of administration | Subcutaneous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C280H435N71O87S6 |
Molar mass | 6380.33 g·mol−1 |
Insulin icodec, sold under the brand name Awiqli, is a medication used for the treatment of diabetes to improve glycemic control. [2] It is an ultralong-acting basal insulin analogue that is developed by Novo Nordisk. [2]
It has a plasma half-life more than eight days [5] (compared to 25 hours of the previous longest-acting insulin analogue insulin degludec), making it a once-weekly basal insulin. [5]
Like insulin, icodec is composed of two peptide chains linked by a disulfide bridge. However, a C20 fatty diacid-containing side chain has been added for strong, reversible albumin binding; and three amino acid substitutions provide molecular stability and attenuate insulin receptor binding and clearance. Together, these modifications prolong the half-life. [6]
Insulin icodec was approved for medical use in Canada in March 2024. [2]
In March 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Awiqli, intended for the treatment of diabetes. [3] The applicant for this medicinal product is Novo Nordisk A/S. [3] Insulin icodec was approved for medical use in the European Union in May 2024. [4]
Insulin icodec is the international nonproprietary name. [7]
Based on a clinical trial, glycemic control was found to be non-inferior with once-weekly insulin icodec compared with once-daily insulin glargine U100. [8]